Overview
Mokola virus (MOKV) is a lyssavirus belonging to the Rhabdoviridae family, causing encephalomyelitis primarily in sub-Saharan Africa. It affects both animals and humans, with no existing vaccine for human or animal protection, distinguishing it from rabies despite their relatedness 1.Diagnosis
Clinical presentation includes encephalitis and meningitis symptoms.
Laboratory diagnosis involves RT-PCR for viral RNA detection in cerebrospinal fluid (CSF) or saliva 1.
Serological testing may be used but lacks specificity due to cross-reactivity issues with other lyssaviruses 1.Management
Supportive care is the mainstay, including management of neurological symptoms and respiratory support as needed.
Antiviral therapy specific to MOKV is not established; ribavirin has shown some efficacy in experimental settings but requires further validation 1.
Prevention of secondary infections through prophylactic antibiotics may be considered 1.Special Populations
Pregnancy: Specific management guidelines are lacking; supportive care remains critical 1.
Pediatrics: Children may present with more severe symptoms; close monitoring and supportive care are essential 1.
Elderly: Increased susceptibility to severe neurological complications necessitates vigilant supportive care 1.
Comorbidities: Patients with underlying neurological conditions may experience exacerbated symptoms; tailored supportive interventions are advised 1.Key Recommendations
Implement supportive care measures including neurological and respiratory support for managing MOKV infection (Evidence: Expert opinion 1).
Consider ribavirin for experimental treatment, though its efficacy requires further clinical validation (Evidence: Weak 1).
Prioritize close monitoring in special populations such as pregnant women, children, elderly patients, and those with comorbidities due to increased risk of severe outcomes (Evidence: Expert opinion 1).References
1 Oladipo EK, Ogunniran JA, Akinpelu OS, Omole TO, Adeyemo SF, Irewolede BA et al.. Bioinformatics designing of an mRNA vaccine for Mokola virus (MOKV) using immunoinformatics as a secure strategy for successful vaccine development. BMC immunology 2024. link